"The View" co-host Whoopi Goldberg addressed a "phony weight loss ad" circulating on Instagram during the show on Wednesday ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Novo Nordisk's Karsten Munk Knudsen is targeting 800 million obese people globally.

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

The EGOT winner railed against an ad that's circulating on social media with a manipulated version of her promoting "bad ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss ...

Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.